Epoetin delta

This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.

Identification

Generic Name
Epoetin delta
DrugBank Accession Number
DB11624
Background

Epoetin Delta is an ingredient in the EMA-withdrawn product Dynepo.

Type
Biotech
Groups
Approved, Investigational, Withdrawn
Biologic Classification
Protein Based Therapies
Other protein based therapies
Protein Chemical Formula
Not Available
Protein Average Weight
Not Available
Sequences
Not Available
Synonyms
  • Epoetin delta
External IDs
  • HMR-4396
  • HMR4396

Pharmacology

Indication

Not Available

Pharmacology
Reduce drug development failure rates
Build, train, & validate machine-learning models
with evidence-based and structured datasets.
See how
Build, train, & validate predictive machine-learning models with structured datasets.
See how
Associated Conditions
Contraindications & Blackbox Warnings
Contraindications
Avoid life-threatening adverse drug events
Improve clinical decision support with information on contraindications & blackbox warnings, population restrictions, harmful risks, & more.
Learn more
Avoid life-threatening adverse drug events & improve clinical decision support.
Learn more
Pharmacodynamics

Not Available

Mechanism of action
Not Available
Absorption

Not Available

Volume of distribution

Not Available

Protein binding

Not Available

Metabolism
Not Available
Route of elimination

Not Available

Half-life

Not Available

Clearance

Not Available

Adverse Effects
Adverseeffects
Improve decision support & research outcomes
With structured adverse effects data, including: blackbox warnings, adverse reactions, warning & precautions, & incidence rates.
Learn more
Improve decision support & research outcomes with our structured adverse effects data.
Learn more
Toxicity

Not Available

Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
DrugInteraction
CyclophosphamideThe risk or severity of pulmonary toxicity can be increased when Epoetin delta is combined with Cyclophosphamide.
VinblastineThe risk or severity of peripheral neuropathy can be increased when Epoetin delta is combined with Vinblastine.
VincristineThe risk or severity of peripheral neuropathy can be increased when Epoetin delta is combined with Vincristine.
VindesineThe risk or severity of peripheral neuropathy can be increased when Epoetin delta is combined with Vindesine.
VinflunineThe risk or severity of peripheral neuropathy can be increased when Epoetin delta is combined with Vinflunine.
VinorelbineThe risk or severity of peripheral neuropathy can be increased when Epoetin delta is combined with Vinorelbine.
Interactions
Identify potential medication risks
Easily compare up to 40 drugs with our drug interaction checker.
Get severity rating, description, and management advice.
Learn more
Food Interactions
Not Available

Products

Products2
Drug product information from 10+ global regions
Our datasets provide approved product information including:
dosage, form, labeller, route of administration, and marketing period.
Access now
Access drug product information from over 10 global regions.
Access now
Brand Name Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing EndRegionImage
DynepoInjection, solution3000 IUIntravenous; SubcutaneousShire Pharmaceutical Contracts Limited2016-09-072009-04-23EU flag
DynepoInjection, solution6000 IUIntravenous; SubcutaneousShire Pharmaceutical Contracts Limited2016-09-072009-04-23EU flag
DynepoInjection, solution5000 IUIntravenous; SubcutaneousShire Pharmaceutical Contracts Limited2016-09-072009-04-23EU flag
DynepoInjection, solution2000 IUIntravenous; SubcutaneousShire Pharmaceutical Contracts Limited2016-09-072009-04-23EU flag
DynepoInjection, solution8000 IUIntravenous; SubcutaneousShire Pharmaceutical Contracts Limited2016-09-072009-04-23EU flag
DynepoInjection, solution4000 IUIntravenous; SubcutaneousShire Pharmaceutical Contracts Limited2016-09-072009-04-23EU flag
DynepoInjection, solution1000 IUIntravenous; SubcutaneousShire Pharmaceutical Contracts Limited2016-09-072009-04-23EU flag
DynepoInjection, solution10000 IUIntravenous; SubcutaneousShire Pharmaceutical Contracts Limited2016-09-072009-04-23EU flag

Categories

Drug Categories
Chemical TaxonomyProvided by Classyfire
Description
Not Available
Kingdom
Organic Compounds
Super Class
Organic Acids
Class
Carboxylic Acids and Derivatives
Sub Class
Amino Acids, Peptides, and Analogues
Direct Parent
Peptides
Alternative Parents
Not Available
Substituents
Not Available
Molecular Framework
Not Available
External Descriptors
Not Available
Affected organisms
Not Available

Chemical Identifiers

UNII
474EI5756Y
CAS number
261356-80-3

References

General References
Not Available
Not Available

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
4TerminatedOtherAnemia / Renal Failure, Chronic Renal Failure1
3TerminatedTreatmentAnemia / Kidney Failure1
Not AvailableTerminatedNot AvailableAnemia / Kidney Diseases / Renal Failure, Chronic Renal Failure1

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage Forms
FormRouteStrength
Injection, solutionIntravenous; Subcutaneous1000 IU
Injection, solutionIntravenous; Subcutaneous10000 IU
Injection, solutionIntravenous; Subcutaneous2000 IU
Injection, solutionIntravenous; Subcutaneous3000 IU
Injection, solutionIntravenous; Subcutaneous4000 IU
Injection, solutionIntravenous; Subcutaneous5000 IU
Injection, solutionIntravenous; Subcutaneous6000 IU
Injection, solutionIntravenous; Subcutaneous8000 IU
Prices
Not Available
Patents
Not Available

Properties

State
Not Available
Experimental Properties
Not Available

Drug created on October 17, 2016 20:07 / Updated on February 21, 2021 18:53